Sejersen, Thomas
Graham, Sophie
Ekström, Anne-Berit
Kroksmark, Anna-Karin
Kwiatkowska, Marta
Ganz, Michael L.
Justo, Nahila
Gertow, Karl
Simpson, Alex
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 1 June 2023
Accepted: 25 January 2024
First Online: 20 April 2024
Declarations
:
: Alex Simpson is employed by F.Hoffmann-La Roche Ltd. Karl Gertow is employed by Roche AB, Sweden. Nahila Justo, Michael Ganz, Sophie Graham and Marta Kwiatkowska are employed by Evidera, which provides consulting and other research services to pharmaceutical, medical device, and related organizations. In their salaried positions, they work with a variety of companies and organizations, and are precluded from receiving payment or honoraria directly from these organizations for services rendered. Thomas Sejersen is a recipient of honoraria received for lectures or consultancy from Biogen, Novartis, PTC Therapeutics, Sarepta Therapeutics, Roche, Hansa Biopharma and Sanofi Genzyme. Anne-Berit Ekström is a recipient of honoraria for consultancy from Novartis. Anna-Karin Kroksmark has acted as a clinical evaluator and consultant to Biogen.
: The study was approved by the Swedish Ethical Review Authority DNR:2020–04656.